Janssen’s COVID-19 Vaccine Should Continue To Be Available, CDC Panel Concurs

Benefits of the one-shot vaccine outweigh risk, ACIP members agree. One member says he supports its availability but would personally recommend mRNA vaccines instead.

Janssen COVID-19 vaccine
CDC advisory committee supports continued use of Janssen's COVID-19 vaccine • Source: Alamy

The low incidence of the neurological disorder Guillan-Barré syndrome in those receiving Johnson & Johnson’s COVID-19 vaccine is outweighed by the vaccine’s benefits in protecting against SARS-CoV-2 infection, hospitalization and death, the US Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP) concluded.

At a 22 July meeting, ACIP members were asked to discuss whether the one-shot vaccine, sold by J&J’s Janssen unit,...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers